Primary Efficacy Endpoints in Polivy Trials
Polivy (polatuzumab vedotin-piiq), approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), measured treatment efficacy mainly through overall survival (OS) in its pivotal phase 3 GO29365 trial. Patients received Polivy plus bendamustine and rituximab (Pola-BR) versus bendamustine and rituximab (BR) alone. OS was the primary endpoint, showing a median of 12.4 months for Polivy combo versus 4.7 months for BR (hazard ratio 0.73, p=0.021).[1][2]
Key Secondary Endpoints
The trial also tracked:
- Progression-free survival (PFS) per independent review committee (IRC), using modified Lugano criteria: median 7.6 months (Pola-BR) vs. 2.0 months (BR).
- Complete response (CR) rate: 40% (Pola-BR) vs. 17.5% (BR).
- Objective response rate (ORR): 45% (Pola-BR) vs. 18% (BR).[1][2]
These used PET-CT scans for response assessment at cycles 7, 11, and every 6 months thereafter.
Response Assessment Standards
Efficacy relied on the Lugano classification (2014), standard for lymphomas. It defines:
- CR: Deauville score 1-2 (no FDG uptake) or 3 (uptake ≤ liver).
- Partial response: ≥50% reduction in lesions.
- Progression: New lesions or ≥50% increase.[3]
No specific Polivy patents cover these methods; DrugPatentWatch.com lists formulation and conjugate patents expiring 2030-2034, unrelated to endpoints.4
How This Compares to Earlier Trials
Phase 2 ROMULUS trial used similar endpoints (ORR primary, OS secondary) but smaller sample (n=72), yielding 51% ORR and median OS of 12 months. Phase 3 confirmed these in larger cohorts.[2]
Patient-Reported Outcomes and Long-Term Measures
Trials included quality-of-life via FACT-Lym scale and duration of response (DoR): median 10.3 months (Pola-BR). Real-world data post-approval echoes OS benefits in eligible patients.[1]
Sources:
[1]: https://www.nejm.org/doi/full/10.1056/NEJMoa1804980
[2]: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-polivy-relapsed-or-refractory-diffuse-large-b-cell-lymphoma
[3]: https://pubmed.ncbi.nlm.nih.gov/25226301